Form 4: Cigna COO Exercises Options, Sells Shares Under 10b5-1 Plan

Cigna's President and COO, Brian C. Evanko, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Brian C. Evanko, President and Chief Operating Officer of The Cigna Group, engaged in several transactions involving company stock.
• On October 3, 2025, Evanko exercised employee stock options to acquire 5,368 shares of Common Stock at an exercise price of $139.22 per share.
• Immediately following the option exercise on October 3, 2025, he sold 5,368 shares of Common Stock at a price of $300 per share.
• On October 6, 2025, Evanko exercised additional employee stock options to acquire 901 shares of Common Stock at an exercise price of $139.22 per share.
• The employee stock options were granted on March 1, 2016, and vested in three equal annual installments on the first, second, and third anniversaries of the grant date, with an expiration date of March 1, 2026.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Evanko on May 7, 2025.
• Evanko also beneficially owns 904.1848 shares indirectly through The Cigna Group's 401(k) Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a sale of shares, it was pre-arranged under a 10b5-1 plan, which mitigates negative interpretations. The exercise of options indicates the executive is realizing value, and continued indirect ownership through the 401(k) plan maintains alignment with shareholder interests.

Positives

• The exercise of stock options indicates that the executive is realizing value from previously granted equity compensation.
• The transactions were conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and adherence to insider trading regulations, reducing concerns about opportunistic trading.
• Continued indirect ownership of shares through the 401(k) plan shows ongoing alignment with shareholder interests.

Negatives

• The sale of 5,368 shares by a high-ranking executive could be perceived as a reduction in direct ownership, although it was part of a pre-arranged plan.

Future Outlook

The filing indicates that the reported transactions were part of a pre-arranged Rule 10b5-1 trading plan adopted on May 7, 2025, suggesting a structured approach to future equity transactions by the executive.

Industry Context

This filing represents a routine insider transaction for a senior executive at a major healthcare services company. Such transactions are common for executives managing their equity compensation and personal finances, often utilizing 10b5-1 plans to comply with insider trading rules.

Stakeholder Impact

• Shareholders: The transactions provide transparency into executive equity holdings and compensation realization, which can influence investor sentiment regarding management's confidence and financial planning.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. While the sale reduces direct ownership, the pre-planned nature and the executive's continued indirect holdings suggest no immediate change in fundamental outlook for Cigna. A Form 4 alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation; investors should consider broader company performance, industry trends, and financial reports.

Keywords

Cigna Group, CI, Brian C. Evanko, Form 4, Insider Trading, Stock Options, Equity Compensation, 10b5-1 Plan, Common Stock, Executive Transactions